Granted Patent
B2
US 12,226,422 · App. 17/051,016 · Granted Feb 18, 2025
Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
Inventors:
Frank Löscher (Schriesheim, DE); Diana Strehl (Heidelberg, DE); Kirsten Eickhoff (Aschaffenburg, DE)
Assignee:
NOVALIQ GMBH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein the composition comprises tafluprost and a semifluorinated alkane.
Claims (19)
1. A method of treating glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, comprising administering to a patient in need thereof, a pharmaceutical composition consisting of 0.002-0.005% (w/v) tafluprost dissolved in a vehicle consisting of a semifluorinated alkane and up to 3% (w/w) of ethanol.
2. The method of claim 1 , wherein the semifluorinated alkane is 1-perfluorohexyloctane or 1-perfluorobutyl-pentane.
3. The method of claim 1 , wherein the pharmaceutical composition is administered at a target dose per eye of tafluprost in the range of from about 0.20 μg to 0.55 μg.
4. The method of claim 1 , wherein the pharmaceutical composition is topically administered as single drop of about 11 μl volume.
5. The method of claim 1 , wherein the concentration of tafluprost is 0.003% w/v.
6. The method of claim 1 , wherein the concentration of the ethanol is up to 1.5% w/w.
7. The method of claim 1 , wherein the composition is administered to the eye of the patient.
8. The method of claim 7 , wherein the pharmaceutical composition is topically administered in a dose volume per eye of 8 to 15 μl.
9. The method of claim 1 , wherein the composition is administered once daily to the eye of the patient.
10. A pharmaceutical composition consisting of 0.002-0.005% (w/v) tafluprost dissolved in a vehicle consisting of a semifluorinated alkane and up to 3% (w/w) of ethanol.
11. A kit comprising a pharmaceutical composition according to claim 10 , wherein the kit comprises a container for holding the pharmaceutical composition and a drop dispenser for topically administering the composition to the eye of a patient.
12. The kit according to claim 11 , wherein the drop dispenser is adapted for dispensing a single dose of the pharmaceutical composition.
13. The kit according to claim 11 , wherein the container for holding the pharmaceutical composition holds a single dose or a multiple or a plurality of doses of the composition.
14. The pharmaceutical composition of claim 10 , wherein the semifluorinated alkane is 1-perfluorohexyloctane or 1-perfluorobutyl-pentane.
15. The pharmaceutical composition of claim 10 , wherein the concentration of tafluprost is 0.0030% w/v.
16. The method of claim 2 wherein the semifluorinated alkane is 1-perfluorohexyloctane.
17. The method of claim 6 , wherein the concentration of the ethanol is up to 1.0% w/w.
18. The pharmaceutical composition of claim 10 , wherein the semifluorinated alkane is 1-perfluorohexyloctane.
19. The method of claim 3 , wherein the target dose per eye of tafluprost is 0.33 μg.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 9, 2021
From: LOSCHER, FRANK; STREHL, DIANA; EICKHOFF, KIRSTEN
To: NOVALIQ GMBH
Reel/Frame 055882/0319 →
Priority Claims (1)
EP 18169920
· Apr 27, 2018
· regional
Continuity (1)
References Cited (378)
US 2616927A
· Kauck et al.
· 1952
[cited by applicant]
US 4452818A
· Haidt
· 1984
[cited by applicant]
US 4649047A
· Kaswan
· 1987
[cited by applicant]
US 5077036A
· Long
· 1991
[cited by applicant]
US 5126127A
· Bhagwat et al.
· 1992
[cited by applicant]
US 5152997A
· Ebert et al.
· 1992
[cited by applicant]
US 5254338A
· Sakai et al.
· 1993
[cited by applicant]
US 5326566A
· Parab
· 1994
[cited by applicant]
US 5336175A
· Mames
· 1994
[cited by applicant]
US 5340567A
· Cole et al.
· 1994
[cited by applicant]
US 5370313A
· Beard
· 1994
[cited by applicant]
US 5518731A
· Meadows
· 1996
[cited by applicant]
US 5667809A
· Trevino et al.
· 1997
[cited by applicant]
US 5849291A
· Kessler
· 1998
[cited by applicant]
US 5851544A
· Penska et al.
· 1998
[cited by applicant]
US 5874469A
· Maniar et al.
· 1999
[cited by applicant]
US 5874481A
· Weers et al.
· 1999
[cited by applicant]
US 5904933A
· Riess et al.
· 1999
[cited by applicant]
US 5980936A
· Krafft et al.
· 1999
[cited by applicant]
US 5981607A
· Ding
· 1999
[cited by applicant]
US 6042845A
· Sun et al.
· 2000
[cited by applicant]
US 6060085A
· Osborne
· 2000
[cited by applicant]
US 6113919A
· Reiss et al.
· 2000
[cited by applicant]
US 6140374A
· May et al.
· 2000
[cited by applicant]
US 6159977A
· Reeves
· 2000
[cited by applicant]
US 6177477B1
· George et al.
· 2001
[cited by applicant]
US 6197323B1
· Georgieff
· 2001
[cited by applicant]
US 6224887B1
· Samour et al.
· 2001
[cited by applicant]
US 6262105B1
· Johnstone
· 2001
[cited by applicant]
US 6262126B1
· Meinert
· 2001
[cited by applicant]
US 6264990B1
· Knepp et al.
· 2001
[cited by applicant]
US 6294563B1
· Garst
· 2001
[cited by applicant]
US 6335335B2
· Higashiyama
· 2002
[cited by applicant]
US 6372243B2
· Kobuch
· 2002
[cited by applicant]
US 6391879B1
· Reeves
· 2002
[cited by applicant]
US 6399087B1
· Zhang et al.
· 2002
[cited by applicant]
US 6458376B1
· Meadows
· 2002
[cited by applicant]
US 6486212B2
· Meinert
· 2002
[cited by applicant]
US 6489367B1
· Meinert
· 2002
[cited by applicant]
US 6528086B2
· Zhang
· 2003
[cited by applicant]
US 6576663B2
· Klimko
· 2003
[cited by applicant]
US 6730328B2
· Maskiewicz et al.
· 2004
[cited by applicant]
US 7001607B1
· Menz et al.
· 2006
[cited by applicant]
US 7026359B1
· Gross
· 2006
[cited by applicant]
US 7041705B2
· Mishra et al.
· 2006
[cited by applicant]
US 7258869B1
· Berry et al.
· 2007
[cited by applicant]
US 7283239B2
· Nonogaki et al.
· 2007
[cited by applicant]
US 7608261B2
· Furfine et al.
· 2009
[cited by applicant]
US 7687445B2
· Bonnet et al.
· 2010
[cited by applicant]
US 7687455B2
· Bonnet et al.
· 2010
[cited by applicant]
US 7740875B2
· Dechow
· 2010
[cited by applicant]
US 7776349B2
· Dechow et al.
· 2010
[cited by applicant]
US 8029977B2
· Meinert
· 2011
[cited by applicant]
US 8222292B2
· Goskonda et al.
· 2012
[cited by applicant]
US 8470873B2
· Chen et al.
· 2013
[cited by applicant]
US 8492334B2
· Lavik et al.
· 2013
[cited by applicant]
US 8614178B2
· Theisinger et al.
· 2013
[cited by applicant]
US 8759281B2
· Bonnet et al.
· 2014
[cited by applicant]
US 8759404B2
· Daftary et al.
· 2014
[cited by applicant]
US 8772337B2
· Pilotaz et al.
· 2014
[cited by applicant]
US 8796340B2
· Theisinger et al.
· 2014
[cited by applicant]
US 8916157B2
· Krause et al.
· 2014
[cited by applicant]
US 8986738B2
· Meinert
· 2015
[cited by applicant]
US 9005626B2
· Seigfried
· 2015
[cited by applicant]
US 9023898B2
· Wong et al.
· 2015
[cited by applicant]
US 9186305B1
· Suzuki
· 2015
[cited by applicant]
US 9241900B2
· Wilson
· 2016
[cited by applicant]
US 9308262B2
· Günther et al.
· 2016
[cited by applicant]
US 9757459B2
· Theisinger et al.
· 2017
[cited by applicant]
US 9757460B2
· Günther et al.
· 2017
[cited by applicant]
US 9770508B2
· Günther et al.
· 2017
[cited by applicant]
US 9968678B2
· Theisinger et al.
· 2018
[cited by applicant]
US 9982032B2
· Park et al.
· 2018
[cited by applicant]
US 20020004063A1
· Zhang
· 2002
[cited by applicant]
US 20020128527A1
· Meinert
· 2002
[cited by applicant]
US 20020137793A1
· Klimko
· 2002
[cited by applicant]
US 20020198266A1
· Meinert
· 2002
[cited by applicant]
US 20030018044A1
· Peyman
· 2003
[cited by applicant]
US 20030027833A1
· Cleary et al.
· 2003
[cited by applicant]
US 20030170194A1
· Piotrowiak
· 2003
[cited by applicant]
US 20040044045A1
· Burk
· 2004
[cited by applicant]
US 20040101551A1
· Selzer
· 2004
[cited by applicant]
US 20040265362A1
· Susilo
· 2004
[cited by applicant]
US 20050075407A1
· Tamarkin et al.
· 2005
[cited by applicant]
US 20050079210A1
· Gupta
· 2005
[cited by applicant]
US 20050084553A1
· Moon et al.
· 2005
[cited by applicant]
US 20050175541A1
· Lanza et al.
· 2005
[cited by applicant]
US 20050288196A1
· Horn
· 2005
[cited by applicant]
US 20060009522A1
· Dana et al.
· 2006
[cited by applicant]
US 20060078580A1
· Dechow
· 2006
[cited by applicant]
US 20070238732A1
· Graham et al.
· 2007
[cited by applicant]
US 20080019926A1
· Krafft et al.
· 2008
[cited by applicant]
US 20080050335A1
· Faour et al.
· 2008
[cited by applicant]
US 20080089923A1
· Burkstrand et al.
· 2008
[cited by applicant]
US 20080112895A1
· Kottayil et al.
· 2008
[cited by applicant]
US 20080153909A1
· Dana et al.
· 2008
[cited by applicant]
US 20080207537A1
· Turner et al.
· 2008
[cited by applicant]
US 20080254106A1
· Bell
· 2008
[cited by applicant]
US 20080260656A1
· Mallard
· 2008
[cited by applicant]
US 20090136430A1
· Dugger
· 2009
[cited by applicant]
US 20100006600A1
· Dascanio
· 2010
[cited by applicant]
US 20100189765A1
· Erickson et al.
· 2010
[cited by applicant]
US 20100305081A1
· Dechow
· 2010
[cited by applicant]
US 20110223208A1
· Hill et al.
· 2011
[cited by applicant]
US 20110269704A1
· Seigfried
· 2011
[cited by applicant]
US 20120100183A1
· Schlessinger et al.
· 2012
[cited by applicant]
US 20120219640A1
· Wright
· 2012
[cited by applicant]
US 20130309226A1
· Armstrong et al.
· 2013
[cited by applicant]
US 20140004197A1
· Theisinger et al.
· 2014
[cited by applicant]
US 20140186350A1
· Ghosh et al.
· 2014
[cited by applicant]
US 20150174096A1
· Bottger et al.
· 2015
[cited by applicant]
US 20160000941A1
· Keller et al.
· 2016
[cited by applicant]
US 20160303031A1
· El Achkar et al.
· 2016
[cited by applicant]
US 20170087100A1
· Scherer et al.
· 2017
[cited by applicant]
US 20170216204A1
· Theisinger et al.
· 2017
[cited by applicant]
US 20170348285A1
· Hellstron
· 2017
[cited by applicant]
US 20180360908A1
· Beier et al.
· 2018
[cited by applicant]
US 20190256591A1
· Günther et al.
· 2019
[cited by applicant]
US 20190328717A1
· Günther et al.
· 2019
[cited by applicant]
US 20190343793A1
· Günther et al.
· 2019
[cited by applicant]
US 20210069014A1
· Löscher et al.
· 2021
[cited by applicant]
US 20210121471A1
· Löscher et al.
· 2021
[cited by applicant]
US 20210315832A1
· Scherer et al.
· 2021
[cited by applicant]
US 20210346313A1
· Beier et al.
· 2021
[cited by applicant]
US 20220008397A1
· Xu et al.
· 2022
[cited by applicant]
US 20220031844A1
· Mauden et al.
· 2022
[cited by applicant]
US 20220079925A1
· Günther et al.
· 2022
[cited by applicant]
US 20220354786A1
· Friess et al.
· 2022
[cited by applicant]
US 20230330056A1
· Günther et al.
· 2023
[cited by applicant]
CN 202136470
· 2012
[cited by applicant]
CN 203524843U
· 2014
[cited by applicant]
EP 0089815
· 1983
[cited by applicant]
EP 0593552
· 1994
[cited by applicant]
EP 0670159A1
· 1995
[cited by applicant]
EP 1152749B1
· 2006
[cited by applicant]
JP S6452722
· 1989
[cited by applicant]
JP 2000511157
· 2000
[cited by applicant]
JP 2001158734
· 2001
[cited by applicant]
JP 2011006348
· 2011
[cited by applicant]
JP 2011024841A
· 2011
[cited by applicant]
WO WO1998005301
· 1998
[cited by applicant]
WO WO00054588
· 2000
[cited by applicant]
WO WO2003099258
· 2003
[cited by applicant]
WO WO2008136034
· 2008
[cited by applicant]
WO WO2010146536
· 2010
[cited by applicant]
WO WO2011113855A2
· 2011
[cited by examiner]
WO WO2016082644
· 2016
[cited by applicant]
WO WO2016108130
· 2016
[cited by applicant]
Zioptan Drug Label DailyMed, NIH, 2017 (Year: 2017).
[cited by examiner]
Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment Kumar et al. J. Adv. Pharm. Tech. Res. 2011 (Year: 2011).
[cited by examiner]
Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension Aihara et al. Clinical Ophthalmology 2010:4 163-170 (Year: 2010).
[cited by examiner]
Anonymous, “Semifluorinated alkane technology brings advantages for topical therapy,” Ophthalmology Times, pp. 1-2 (2016) http://www.ophthalmologytimes.com/ophthalmology/semifluorinated-alkane-technology-brings-advantag…
[cited by applicant]
Anonymous, “Highlights of Prescribing Information: Zioptan”, pp. 1-11 (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202514s003s004lbl.pdf.
[cited by applicant]
Ahmed, I. et al., “Disposition of Timolol and Inulin in the Rabbit Eye Following Corneal Versus Non-Corneal Absorption,” International Journal of Pharmaceutics, 1987, 38, 9-21.
[cited by applicant]
Agarwal, et al., “Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs,” International Journal of Pharmaceutics, 538(1-2):119-129 (2018).
[cited by applicant]
Baerdemaeker, “Pharmacokinetics in Obese Patients,” Continuing Education in Anaesthesia, Critical Care & Pain, 2004, 4, 152-155.
[cited by applicant]
Barata-Vallejo et al., “(Me3Si)3SiH-Mediated Intermolecular Radical Perfluoroalkylation Reactions of Olefins in Water,” J. Org. Chem., 2010, 75:6141-6148.
[cited by applicant]
Bardin et al., “Long-Range Nanometer-Scale Organization of Semifluorinated Alkane Monolayers at the Air/Water Interface,” Langmuir, 2011, 27:13497-13505.
[cited by applicant]
Bertilla et al., “Semifluorinated Alkanes as Stabilizing Agents of Fluorocarbon Emulsions,” Springer, 2005, vol. 12, 24 pages.
[cited by applicant]
Blackie et al., “MGD: Getting to the Root Cause of Dry Eye”, Review of Optometry, 2012, pp. 1-12.
[cited by applicant]
Broniatowski, M. et al., “Langmuir Monolayers Characteristics of Perfluorodecyl)-Alkanes,” Journal of Physical Chemistry B, 2004, 108, 13403-13411.
[cited by applicant]
Chao, W. et al., “Report of the Inaugural Meeting of the TFOS i2 = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment,” (London, United Kingdom, Mar. 21, 2015) Accepted Manuscript, Accepted Dat…
[cited by applicant]
Chhadva et al., “Meibomian Gland Disease the Role of Gland Dysfunction in Dry Eye Disease,” Ophthalmology (2017) 124(11 Supplement): S20-S26.
[cited by applicant]
Chemical Book, 5-Fluorouracil, available at <http://www.chemicalbook.com/ChemicalProductProperty_EN_CB8162744.htm>, accessed Mar. 7, 2014, 1 page.
[cited by applicant]
Costa Gomes et al., “Solubility of dioxygen in seven fluorinated liquids,” Journal of Fluorine Chemistry, 2004, 125, 1325-1329.
[cited by applicant]
Davies, N., “Biopharmaceutical Considerations in Topical Ocular Drug Delivery,” Clinical and Experimental Pharmacology and Physiology, 2000, 27, 558-562.
[cited by applicant]
Dembinski, R. et al., “Semi-fluorinated Alkanes as Carriers for Drug Targeting in Acute Respiratory Failure,” Experimental Lung Research, 2010, 36, 499-507.
[cited by applicant]
Dias et al., “Solubility of oxygen in liquid perfluorocarbons,” Fluid Phase Equilibria, 2004, 222-223:325-330.
[cited by applicant]
Dutescu, R.M. et al., “Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, 2014, pp. 123-128.
[cited by applicant]
Elkeeb, R. et al., “Transungual Drug Delivery: Current Status,” International Journal of Pharmaceutics, 2010, 384, 1-8.
[cited by applicant]
English-language machine translation of EP0670159 (A1) issued in U.S. Appl. No. 14/122,025 on Apr. 1, 2015, 10 pages.
[cited by applicant]
Freiburger Dokumentenserver (FreiDok), Albert-Ludwigs-Unversität Freiburg, retrieved from http://www.freidok.uni-freiburg.de/volltexte/5682/, retrieved on Feb. 5, 2014, 2 pages.
[cited by applicant]
Gayton, J., “Etiology, Prevalence, and Treatment of Dry Eye Disease,” Clinical Ophthalmology, 2009, 3, 405-412.
[cited by applicant]
Gehlsen. U., et al., “Cyclosporine A using F4H5 as liquid drug carrier is effective in treating experimental dry-eye disease,” Investigative Ophthalmology & Visual Science, 2015, 56(7):319, Abstract Only (2 pages).
[cited by applicant]
Gehlsen et al., “A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye,” Graefe's Arch. Clin. Exp. Ophthalmol., (2017) 255(…
[cited by applicant]
Gehlsen, U., et al., “Omega-3 Fatty Acids Using F6H8-Carrier as Topical Therapy in Experimental Dry-Eye Disease,” Investigative Ophthalmology & Visual Science, 2016, 57:417, Abstract Only (1 page).
[cited by applicant]
Gerdenitsch, “Emulsions—established and promising drug carriers for parenteral adminstration”, International Pharmaceutical Industry, 62-62, retrieved from internet: http://ipimediaworld.com/wp-content/uploads/2012/05/P…
[cited by applicant]
German, E.J., et al., “Reality of drop size from multi-dose eye drop bottles: is it cause for concern?” Eye, 1999, 13:93-100.
[cited by applicant]
Griffin, W., “Classification of Surface-Active Agents by ‘HLB’,” Journal of the Society of Cosmetic Chemists, 1949, 1, 311-326.
[cited by applicant]
Gopal et al., “Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration,” Indian J Ophthalmol., 2007, 55(6):431-435, (8 pages).
[cited by applicant]
Hardung, H., “Semifluorierte und perfluorierte Verbindungen zur topischen und parenteralen Anwendung,” 2008, English Language Abstract, 2 pages, retrieved from https://freidok.uni-freiburg.de/data/5682 (retrieved on Jul…
[cited by applicant]
Hoerauf, H. et al., “Combined Use of Partially Fluorinated Alkanes, Perfluorocarbon Liquids and Silicone Oil: An Experimental Study,” Graefe's Archive for Clinical and Experimental Ophthalmology, 2001, 239 (5), 373-381.
[cited by applicant]
Holm, R. et al., “A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs,” European Journal of Pharmaceutical Sciences, 2011, 42, 416-422.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2011/053949 dated Sep. 18, 2012, 9 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2011/068141 Apr. 23, 2013, 4 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2011/069795 dated May 14, 2013, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2012/050043 dated Jul. 10, 2013, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2012/059787 dated Nov. 26, 2013, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2012/059788 dated Nov. 26, 2013, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2013/051163 dated Jul. 29, 2014, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2013/068882 Mar. 17, 2015, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2013/068909 Mar. 17, 2015, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2014/065840 Jan. 26, 2016, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2017/065163 Dec. 25, 2018, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2017/073697 Mar. 26, 2019, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2017/074079 Mar. 26, 2019, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2017/074545 Apr. 2, 2019, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2017/082739 Jun. 25, 2019, 7 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2011/053949 mailed Sep. 6, 2011, 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2011/068141 mailed Dec. 14, 2011, 2 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2011/069795 mailed Jan. 16, 2012, 3 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2012/050043 mailed Apr. 24, 2012, 2 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2012/059787 mailed Dec. 5, 2012, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2012/059788 mailed Dec. 3, 2012, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2013/051163 mailed Mar. 4, 2013, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2013/068882 mailed Oct. 30, 2013, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2013/068909 mailed Dec. 5, 2013, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2014/065840 mailed Oct. 7, 2014, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2016/073262 mailed Nov. 18, 2016, 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2016/073263 mailed Dec. 23, 2016, 3 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/065163, mailed Aug. 8, 2017, 3 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/073697 mailed Nov. 6, 2017, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/074545 mailed Nov. 28, 2017, 3 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/074079 mailed Dec. 22, 2017, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/082739 mailed Mar. 6, 2018, 3 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/083770 (revised version) mailed Jul. 6, 2018, 4 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2017/083770 mailed Jul. 6, 2018, 14 pages.
[cited by applicant]
International Search Report for International Application No. PCT/EP2019/055149 mailed May 27, 2019, 4 pages.
[cited by applicant]
Ishizaki et al., “Treatment of Diabetic Retinopathy”, Forum: Complication, Practice, 2009, 26(5): 474-476 (3 pages).
[cited by applicant]
JP 2000511157A, English Machine Translation of the Abstract, Description, and Claims, Espacenet, Date Accessed: Feb. 10, 2016.
[cited by applicant]
JPS6452722, English Machine Translation of the Abstract, Description, and Claims, Espacenet, Date Accessed: Feb. 10, 2016.
[cited by applicant]
Jonas et al., “Intravitreal triamcinolone acetonide for exudative age-related macular degeneration,” Br J Ophthalmol, 2003, 87:462-468.
[cited by applicant]
Joussen et al., “The concept of heavy tamponades—chances and limitations,” Graefes Arch Exp Ophthalmol, 2008, 246:1217-1224.
[cited by applicant]
Kaercher et al., “NovaTears® as new Therapy in Dry Eye Results from three prospective, multicenter, non-interventional studies in different patient populations”, TFOS Conference (Tear Film & Ocular Surface), Sep. 7-10, …
[cited by applicant]
Knepp, V. et al., “Stability of Nonaqueous Suspension Formulations of Plasma Derived Factor IX and Recombinant Human Alpha Interferon at Elevated Temperatures,” Pharmaceutical Research, 1998, 15 (7), 1090-1095.
[cited by applicant]
Kociok, N., et al., “Influence on Membrane-Mediated Cell Activation by Vesicles of Silicone Oil or Perfluorohexyloctane,” Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 345-358.
[cited by applicant]
Lallemand et al., “Cyclosporine A delivery to the eye: a pharmaceutical challenge,” European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56(3):307-318, Abstract Only (1 page).
[cited by applicant]
Lemp, M., “Management of Dry Eye Disease,” The American Journal of Managed Care, 2008, 14 (3), S88-S101.
[cited by applicant]
Lin, H. et al., “Dry eye disease: A review of diagnostic approaches and treatments,” Saudi Journal of Ophthalmology, 2014, 28:173-181.
[cited by applicant]
Mackiewicz, J. et al., “In Vivo Retinal Tolerance of Various Heavy Silicone Oils,” Investigative Ophthalmology & Visual Science, 2007, 48 (4), 1873-1883.
[cited by applicant]
Mantle et al., “Adverse and beneficial effects of plant extracts on skin and skin disorders,” Adverse Drug Reaction and Toxicological Reviews, 2001, 20(2): 89-103.
[cited by applicant]
Meinert, H. et al., “Semifluorinated Alkanes—A New Class of Compounds with Outstanding Properties for Use in Ophthalmology,” European Journal of Ophthalmology, 2000, 10 (3), 189-197.
[cited by applicant]
Meinert, H. et al., “The Use of Semifluorinated Alkanes in Blood-Substitutes,” Biomaterials, Artificial Cells, and Immobilization Biotechnology, 1993, 21 (5), 583-595.
[cited by applicant]
Messmer, E.M., “The Pathophysiology, Diagnosis, and Treatment of Dry Eye Disease,” (2015) Deutsches Arzteblatt International, 112(5):71-82.
[cited by applicant]
Messmer, et al. “Semifluorinated Alkanes as a Therapy for Meibomian Gland Dysfunction Results of a prospective, multi-centered observational study”, Presentation, DOG-Kongress, Sep. 29, 2016-Oct. 2, 2016, Berlin DOG (De…
[cited by applicant]
Messmer, et al. “Semifluorinated Alkanes as a Therapy for Meibomian Gland Dysfunction Results of a prospective, multi-centered observational study”, Presentation, DOG-Kongress, Sep. 29, 2016-Oct. 2, 2016, Berlin DOG (De…
[cited by applicant]
Murdan, S., “Enhancing the Nail Permeability of Topically Applied Drugs,” Expert Opinion on Drug Delivery, 2008, 5 (11), 1267-1282.
[cited by applicant]
O'Rourke, M. et al., “Enhancing Delivery of Topical Ocular Drops,” Cataract & Refractive Surgery Today Europe, 2016, 2 pages.
[cited by applicant]
Perry, H., “Dry Eye Disease: Pathophysiology, Classification, and Diagnosis,” The American Journal of Managed Care, 2008, 14 (3), S79-S87.
[cited by applicant]
Pflugfelder et al., “Treatment of Blepharitis: Recent Clinical Trials,” 2014, 12(4):273-284, Abstract Only (2 pages).
[cited by applicant]
Pflugfelder et al., “The Pathophysiology of Dry Eye Disease What We Know and Future Directions for Research,” Ophthalmology (2017) 124(11 Supplement): S4-S13.
[cited by applicant]
Pinarci, E. et al., “Intraocular Gas Application in the Diagnosis and Treatment of Valsalva Retiopathy in Case with Premacular Hemorrhage,” XP002625604, Retina-Vitreus, 2009, 17 (2), 153-155, (Abstract only).
[cited by applicant]
Plassmann, M. et al., “Trace Analytical Methods for Semifluorinated n-Alkanes in Snow, Soil, and Air,” Analytical Chemistry, 2010, 82 (11), 4551-4557.
[cited by applicant]
Plassmann, M. et al., “Theoretical and Experimental Simulation of the Fate of Semifluorinated n-Alkanes During Snowmelt,” Environmental Science & Technology, 2010, 44(17), 6692-6697.
[cited by applicant]
Rosca-Casian, O. et al., “Antifungal Activity of Aloe vera Leaves,” Fitoterapia, 2007, 28, 219-222.
[cited by applicant]
Rosenberg, A., “Effects of Protein Aggregates: An Immunologic Perspective,” The AAPS Journal, 2006, 8 (3), E501-E507.
[cited by applicant]
Sall, K. et al. “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease,” Ophthalmology, 2000, 107(4):631-639.
[cited by applicant]
Sato et al., “Vitrectomy and Intraocular Lens Implantation for Cytomegalovirus Retinitis in a Patient with Acquired Immunodeficiency Syndrome,” Presented by Medical Online, New Ophthalmology, 1999, 16(7): 995-998 (4 pag…
[cited by applicant]
Schnetler et al., “Lipid composition of human meibum: a review,” S Afr Optom, 2013, 72(2), 86-93.
[cited by applicant]
Schmutz et al., “Fluorinated Vesicles Made from Combinations of Phospholipids and Semifluorinated Alkanes. Direct Experimental Evidence of the Location of the Semifluorinated Alkane within the Bilayer”, Langmuir, 2003, …
[cited by applicant]
SPöler et al., “Towards a New in vitro Model of Dry Eye: The ex vivo Eye Irritation Test,” Developments in Ophthalmology, 2010, 45, 93-107.
[cited by applicant]
Steven, P. et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study” Journal of Ocular Pharmacology and Therapeutics (2015) vol. 31, No. 8, pp. 498-503.
[cited by applicant]
Steven et al., “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease,” Journal of Ocular Pharmacology and Therapeutics, 2017, 33(9):1-8.
[cited by applicant]
Steven, P. et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study,” Investigative Ophthalmology & Visual Science, 2015, 56:4493, Abstract Only (1 pag…
[cited by applicant]
Stevenson, C., “Characterization of Protein and Peptide Stability and Solubility in Non-Aqueous Solvents,” Current Pharmaceutical Biotechnology, 2000, 1, 165-182.
[cited by applicant]
Tamura et al., “Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats,” Journal of Pharmaceutical Sciences, 2002, 91(3):719-72…
[cited by applicant]
Tiffany, J.M., “Individual Variations in Human Meibomian Composition,” Exp. Eye Res., 1978, 27, 289-300.
[cited by applicant]
Troiano et al., “Effect of Hypotonic .4% Hyaluronic Acid Drops in Dry Eye Patients: A Cross-Study”, Cornea 27(10): 1126-1130, 1 page (Abstract Only).
[cited by applicant]
Wang, W., “Lyophilization and Development of Solid Protein Pharmaceuticals,” International Journal of Pharmaceutics, 2000, 203, 1-60.
[cited by applicant]
Wong, D. et al., “Perfluorocarbons and Semifluorinated Alkanes,” Seminars in Ophthalmology, 2000, 15 (1), 25-35.
[cited by applicant]
Ujiie et al., “Successful Treatment of Nail Lichen Planus with Topical Tacrolimus”, Department of Dermatology, 2009.
[cited by applicant]
“What is retinal vitrectomy?” Presented by: Medical Online, Obesity and Diabetes Mellitus, 2005, 4(2): 284-286 (3 pages).
[cited by applicant]
Wirta, David L. et al., “A Clinical Phase II Study to Assess Efficacy, Safety and Tolerability of Waterfree Cyclosporine Formulation for the Treatment of Dry Eye Disease,”
[cited by applicant]
Xalatan, Latanoprost Ophthalmic Solution, 50 μg/mL Prostaglandin F
[cited by applicant]
Zakeri et al., “Topical calcipotriol therapy in nail psoriasis”, A study of 24 cases, Dermatology Online Journal, 2005.
[cited by applicant]
Zhang et al., “Surface micelles of semifluorinated alkanes in Langmuir-Blodgett monolayers,” Phys. Chem. Chem. Phys., 2004, 6:1566-1569.
[cited by applicant]
“EvoTears, Product Description” Accessed Online: Dec. 21, 2023. https://evotears.com/at/das-produkt/ (Year: 2017).
[cited by applicant]
“Novaliq GmbH Begins Phase II Clinical Trial of Cyclasol for the Treatment of Moderate to Severe Dry Eye Disease,” (online), 5 pages, (2016); retrieved on Jan. 8, 2021 from the Internet: https://www.biospace.com/article…
[cited by applicant]
Agrahari, et al., “A comprehensive insight on ocular pharmacokinetics,” Drug Delivery and Translational Research, vol. 6, No. 6, pp. 735-754, (2016).
[cited by applicant]
Babu, K., et al. “Medical Management of Uveitis—Current Trends,” Indian J Opthalmol., vol. 61, No. 6, p. 277-283, (2013).
[cited by applicant]
Cabral et al., “Retinal and choroidal angiogenesis: a review of new targets,” International Journal of Retina and Vitreous, vol. 3, No. 31, (2017).
[cited by applicant]
Daull, P., et al. “Distribution of Cyclosporine A in Ocular Tissues After Topical Administration of Cyclosporine A Cationic Emulsions to Pigmented Rabbits,” Cornea, vol. 32, No. 3, p. 345-354, (2013); Abstract Only.
[cited by applicant]
Deschamps, J. et al., “Solubility of oxygen, carbon dioxide and water in semifluorinated alkanes and in perfluorooctylbromide by molecular simulation”, Journal of Fluorine Chemistry, Elsevier, vol. 125, No. 3, (2004).
[cited by applicant]
Kerns et al., Drug-Like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization, Elsevier, Chapter 10, Section 10.4.3, 133, (2008).
[cited by applicant]
Lallemand et al., “Cyclosporine Delivery to the Eye: A comprehensive Review of Academic and Industrial Efforts,” European Journal of Pharmaceutics and Biopharmaceutics,, vol. 117, pp. 14-28, (2017).
[cited by applicant]
Rojas-Carabali, W., et al. “Clinical relationships between dry eye disease and uveitis: a scoping review,” Journal of Ophthalmic Inflammation and Infection, vol. 13, No. 2, (2023).
[cited by applicant]
Scherer et al., “Eyesol: A Novel Topical Ocular Drug Delivery System for Poorly Soluble Drugs,” Drug Development & Delivery, vol. 13, No. 1, pp. 40-44, (2013).
[cited by applicant]
Sheppard et al., “A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 Essence Study,” Cornea, vol. 40, No. 10, pp. 1290-1297, (2021).
[cited by applicant]
Torkildsen et al., “A Clinical Phase 2 Study to Assess Safety, Efficacy, and Tolerability of CyclASol for the Treatment of Dry Eye Disease,” Poster Presentation at American Academy of Ophthalmology (AAO), New Orleans (2…
[cited by applicant]
Yaoxue Zhuanye Zhishi II (Editor: Jin Xiangqun), Military Medical Science Press, 1st Printing of 2nd Edition, Mar. 2009, p. 158.
[cited by applicant]
Yaoxue Zhuanye Zhishi II (Editor: Jin Xiangqun), Military Medical Science Press, 1st Printing of 2nd Edition, Mar. 2009, p. 158, 3 pages (English Machine Translation).
[cited by applicant]
Cited By (5)